Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.64 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22832038 | 0.82 | PARP1 (0.56) | PARP1ACVR1PDPK1CHEK1PIM1 | |
| SCHEMBL11489074 | 0.82 | PARP1 (0.60) | PARP1ACVR1PDPK1CHEK1PIM1 | |
| SCHEMBL21550782 | 0.82 | PARP1 (0.60) | PARP1ACVR1PDPK1CHEK1PIM1 | |
| SCHEMBL11485473 | 0.82 | PARP1 (0.60) | PARP1ACVR1PDPK1CHEK1PIM1 | |
| SCHEMBL24854273 | 0.80 | PARP1 (0.57) | PARP1ACVR1PDPK1CHEK1PIM1 | |
| SCHEMBL23588625 | 0.80 | PARP1 (0.57) | PARP1ACVR1PDPK1CHEK1PIM1 | |
| SCHEMBL24804401 | 0.80 | PARP1 (0.57) | PARP1ACVR1PDPK1CHEK1PIM1 | |
| SCHEMBL2317275 | 0.78 | PARP1 (1.00) | PARP1ACVR1PDPK1CHEK1PIM1 | |
| SCHEMBL29563063 | 0.78 | PARP1 (1.00) | PARP1ACVR1PDPK1CHEK1PIM1 | |
| SCHEMBL20435417 | 0.78 | PARP1 (0.54) | PARP1ACVR1PDPK1CHEK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
| WO-2021129820-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUND | 微境生物医药科技(上海)有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-20180215737-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, CDKN1A | PARP1 193/4885ACVR1 1644/4885PDPK1 108/4885 |
| US-20230002382-A1 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | KRAS, NRAS, HRAS | PARP1 2399/4885ACVR1 4208/4885PDPK1 389/4885 |
| US-20180215737-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF | HCRTR1, HCRTR2, NPY5R | PARP1 3285/4885ACVR1 3944/4885PDPK1 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.